https://www.prnewswire.com/news-releases/cansino-biologics-and-precision-nanosystems-announce-collaboration-to-co-develop-a-covid-19-rna-vaccine-301062328.html?utm_source=STAT+Newsletters&utm_campaign=e04b7ae324-stat_china_COPY_01&utm_medium=email&utm_term=0_8cab1d7961-e04b7ae324-149692869

CanSino taps Canada’s Precision NanoSystems as Covid-19 mRNA vaccine partner

Last week, CanSino Biologics also partnered with Vancouver-based nanotechnology company Precision NanoSystems to launch its second Covid-19 vaccine project, this time using mRNA, the same type of vaccine currently being developed by Moderna.

Looking to catch up with the Cambridge, Mass.-based biotech’s program, now in Phase 2, CanSino will leverage Precision NanoSystems’ nanoparticle technology and RNA vaccine platform to develop a mRNA lipid nanoparticle vaccine against Covid-19.

Unlike its Ad5-nCoV vaccine, the mRNA vaccine will deliver the genetic sequence of the virus enclosed in lipid nanoparticles into patients to try to trigger the immune system to produce antibodies against it.

Under the terms of the agreement, Precision NanoSystems will develop the mRNA vaccine. CanSino will take on the clinical testing, regulatory filing, and commercialization of the product